OPKO Health Inc - Company Profile
Powered by 
All the data and insights you need on OPKO Health Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date OPKO Health Inc Strategy Report
- Understand OPKO Health Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
OPKO Health Inc (OPKO) discovers, develops, manufactures, and commercializes novel diagnostic technologies and pharmaceuticals products. The company’s product portfolio includes 4K score test used for diagnosis of prostate cancer; Rayaldee (calcifediol), an extended-release capsule for treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease; and the Claros analyzer, a blood performance test. OPKO develops products using proprietary technologies including, Carboxyl Terminal Peptide (CTP) technology, Reversible PEGylation and AntagoNAT technology. It is advancing pipeline products targeted for the treatment of hypophosphatemia, obesity, diabetes, haemophilia, growth hormone deficiency, dravet syndrome and other diseases. It also offers veterinary products. The company has operational presence with offices located in Chile, Mexico, Spain, Ireland, Canada, and Israel. OPKO is headquartered in Miami, Florida, the US.
Headquarters
United States of America
Address
4400 Biscayne Blvd., Miami, Florida, 33137
Website
www.opko.com
Telephone
1 305 5754181
No of Employees
3,930
Industry
Medical Equipment
Ticker Symbol & Exchange
OPK (NASD)
Revenue (2022)
$863.5M
-14%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
42.5%
(2022 vs 2021)
Market Cap*
$857.3M
Net Profit Margin (2022)
XYZ
33.1%
(2022 vs 2021)
* As of and is in US$
OPKO Health Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| 4Kscore Test- Diagnosis of Prostate Cancer | Rayaldee |
| Rayaldee- Secondary Hyperparathyroidism in Stage 3 and 4 CKD Patients | Alpharen |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In March, the company signed an agreement to sale assets of BioReference Health to Labcorp. |
| 2023 | Contracts/Agreements | In October, the company entered into a distribution agreement with NextPlat to launch an OPKO Health-branded online storefront on Alibaba Group Holding Limited’s Tmall Global e-commerce platform in China. |
| 2023 | Contracts/Agreements | In September, ModeX Therapeutics awarded a contract from the Biomedical Advanced Research and Development Authority to advance a platform and specific candidates designed to address a range of public health threats in viral infectious diseases. |
Competitor Comparison
| Key Parameters | OPKO Health Inc | Novartis AG | Siemens Healthineers AG | Laboratory Corp of America Holdings | Quest Diagnostics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | Germany | United States of America | United States of America |
| City | Miami | Basel | Forchheim | Burlington | Secaucus |
| State/Province | Florida | - | - | North Carolina | New Jersey |
| No. of Employees | 3,930 | 76,057 | 71,400 | 67,000 | 40,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Phillip Frost, M.D., Ph.D. | Chairman; Chief Executive Officer | Executive Board | 2007 | 86 |
| Jane H. Hsiao, Ph.D. | Vice Chairman; Chief Technical Officer | Executive Board | 2007 | 75 |
| Gary J. Nabel | Director; Chief Innovation Officer | Executive Board | 2020 | - |
| Adam Logal | Chief Financial Officer; Senior Vice President | Senior Management | 2014 | 45 |
| Jane Pine Wood | Chief Legal Officer - BioReference Laboratories | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward